In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform

SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. Here, we present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.

[1]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[2]  G. Ippolito,et al.  Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy , 2020, Clinical Microbiology and Infection.

[3]  Longxiang Xie,et al.  Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV , 2020, Viruses.

[4]  Dominik Wodarz,et al.  ODE models for oncolytic virus dynamics. , 2010, Journal of theoretical biology.

[5]  Maria Alessandra Ragusa,et al.  ODEs approaches in modeling fibrosis: Comment on "Towards a unified approach in the modeling of fibrosis: A review with research perspectives" by Martine Ben Amar and Carlo Bianca. , 2016, Physics of life reviews.

[6]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[7]  Yifan Rao,et al.  The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines , 2020, npj Vaccines.

[8]  Marco Viceconti,et al.  In Silico Trials: Verification, Validation And Uncertainty Quantification Of Predictive Models Used In The Regulatory Evaluation Of Biomedical Products. , 2020, Methods.

[9]  Dong Men,et al.  Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases.

[10]  Steven Y. C. Tong,et al.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.

[11]  Dong Men,et al.  Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients , 2020, medRxiv.

[12]  Francesco Pappalardo,et al.  SimB16: Modeling Induced Immune System Response against B16-Melanoma , 2011, PloS one.

[13]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[14]  Giulia Russo,et al.  Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS) , 2019, BMC Bioinformatics.

[15]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[16]  F. Pappalardo,et al.  The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis , 2020, Cells.

[17]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[18]  Alessandro Lombardo,et al.  A computational model to predict the immune system activation by citrus-derived vaccine adjuvants , 2016, Bioinform..

[19]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[20]  Xiong He,et al.  Risk Factors for SARS among Persons without Known Contact with SARS Patients, Beijing, China , 2004, Emerging infectious diseases.

[21]  J. Barbuto,et al.  Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy , 2019, Front. Immunol..

[22]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[23]  G. Kroemer,et al.  Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.

[24]  J Timmis,et al.  Agent‐Based Modeling in Systems Pharmacology , 2015, CPT: pharmacometrics & systems pharmacology.

[25]  Jiang Gu,et al.  Progress and Prospects on Vaccine Development against SARS-CoV-2 , 2020, Vaccines.

[26]  M. Vignuzzi,et al.  Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics , 2013, PLoS pathogens.

[27]  De-Ming Yang,et al.  A Review of SARS-CoV-2 and the Ongoing Clinical Trials , 2020, International journal of molecular sciences.

[28]  Giulia Russo,et al.  Computational modeling of the expansion of human cord blood CD133+ hematopoietic stem/progenitor cells with different cytokine combinations , 2015, Bioinform..

[29]  Eric Bonabeau,et al.  Agent-based modeling: Methods and techniques for simulating human systems , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Marco Viceconti,et al.  In silico clinical trials: concepts and early adoptions , 2019, Briefings Bioinform..

[31]  Monika Heiner,et al.  Fuzzy Petri nets for modelling of uncertain biological systems , 2018, Briefings Bioinform..

[32]  Emrullah Korkmaz,et al.  Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development , 2020, EBioMedicine.

[33]  L. Rénia,et al.  Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. , 2010, Blood.

[34]  L. Babiuk,et al.  Optimization of a DNA vaccine against SARS. , 2007, DNA and cell biology.

[35]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[36]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[37]  Giulia Russo,et al.  Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus , 2017, BMC Bioinformatics.

[38]  J. Zhao,et al.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[39]  L. Geris,et al.  In silico clinical trials for pediatric orphan diseases , 2018, Scientific Reports.

[40]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[41]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[42]  W. Ko,et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.

[43]  Y. Teo,et al.  Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review , 2020, Journal of clinical medicine.

[44]  Salvatore Musumeci,et al.  Modeling immune system control of atherogenesis , 2008, Bioinform..

[45]  Y. Ho,et al.  SARS-CoV-2: A Storm is Raging. , 2020, The Journal of clinical investigation.

[46]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[47]  Vineet D. Menachery,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States , 2020, Emerging infectious diseases.

[48]  Xuan Li,et al.  Revealing parasite influence in metabolic pathways in Apicomplexa infected patients , 2010, BMC Bioinformatics.

[49]  Francesco Pappalardo,et al.  Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.

[50]  Francesco Pappalardo,et al.  Continuous Petri Nets and microRNA Analysis in Melanoma , 2018, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[51]  A. Rodríguez-Morales,et al.  SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review , 2020 .